Celcuity reports 15.7-month median radiographic progression-free survival with drug combination in prostate cancer patients previously treated with abiraterone

Bitget2026/10/23 13:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Celcuity presented updated Phase 1b/2 results for gedatolisib with darolutamide in metastatic castration-resistant prostate cancer at ESMO on October 23, 2026.
Patients previously treated with abiraterone had longer disease control than those previously treated with enzalutamide.
The combination showed manageable safety, with no treatment-related discontinuations or deaths.
Phase 2 is expected to begin in the first half of 2027 to determine the recommended Phase 3 dose.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230915PRIMZONEFULLFEED9851888) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Celcuity reports 15.7-month median radiographic progression-free survival with drug combination in prostate cancer patients previously treated with abiraterone

You may also like

Crypto prices